KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
Eritrea: Training for Heads of Ministry of Education Branch in Anseba...
Charity's Environment Week Inspires Climate Action Through...
Happy World Wide Web Day - go find out something new and be safe...
United Nations (UN) Tourism/ International Civil Aviation Organization...
Edina Business District Sees Rapid Cleanup by Bedrock Restoration After...
President Ramkalawan Attends 10th Anniversary Celebration of the My First...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment

Biopharmaceutical company KalVista Pharmaceuticals Inc (Nasdaq: KALV) announced on Monday that it has received U.S. Food and Drug Administration (FDA) approval for EKTERLY (sebetralstat), the first and only oral on-demand treatment for acute attacks of hereditary angioedema (HAE) in patients...

If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search